Back to results
US 2017/0360746 A1Published application
Polymorph of granaticin b
AssigneeSloan-Kettering Institute for Cancer Research
InventorTero Kunnari
Life of this patent
Estimating the term…
Abstract
The present invention provides a crystalline Form A of Compound 1, also referred to as Granaticin B, and pharmaceutically compositions thereof. The present invention also provides methods of treating a microbial infection, or a disease, disorder, or condition associated with abnormal cellular proliferation, using crystalline Form A of Compound 1 or pharmaceutical compositions thereof.
Claims34
Crystalline Form A of Compound 1:
(canceled)
(canceled)
(canceled)
14-15. (canceled)
(canceled)
(canceled)
21-27. (canceled)
(canceled)
31-36. (canceled)
(canceled)
40-42. (canceled)
(canceled)
46-49. (canceled)
51-54. (canceled)
Dependencies are inferred from the claim text.